Login to Your Account

Genmab in $53M CNS Antibody Collaboration with Lundbeck

By Cormac Sheridan

Wednesday, October 20, 2010
Genmab A/S is banking €7.5 million (US$10.4 million) up front and could earn up to €30.5 million more from a collaboration with H. Lundbeck A/S to develop antibodies against three central nervous system (CNS) targets. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription